ArticleBMC medical imaging2026
A longitudinal analysis of T1-weighted MRI features associated with progression from mild cognitive impairment to Alzheimer's disease.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Magnetic Resonance Imaging-Based Cortical and Subcortical Volumetric Changes in Alzheimer's Disease: Association with Clinical Severity.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveOur study aimed to systematically identify T1-weighted MRI-derived brain structural features associated with progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD).
methodsWe utilized the data from the Alzheimer's Disease Neuroimaging Initiative (ADNI). A total of 947 participants with MCI at baseline were included. All participants underwent a neuropsychological assessment and clinical diagnosis every 6 months. The longest follow-up period was 15.5 years, with a median follow-up time of 3.0 years (range: 0-15.5 years). During the follow-up period, 314 (33.16%) individuals progressed to AD, while 633 (66.84%) remained stable or reverted to normal cognition. After ComBat-based harmonization to reduce scanner-related batch effects, 192 high-dimensional T1-magnetic resonance imaging (MRI)-derived morphometric and volumetric measures were analyzed. To identify the characteristics associated with AD progression from MCI, we employed a comprehensive analysis framework. Firstly, we applied the penalized generalized estimating equations (PGEE) and mixed effects random forest (MERF) models for feature screening. Based on the union features obtained from these two methods, a high-dimensional joint model (HDJM) was further used to select the key brain structural features. Lastly, a multivariate joint model was employed to capture the influence of the longitudinal MRI trajectories on the MCI-to-AD conversion.
resultsWe identified 8 brain structural features from 192 MRI features that were associated with the risk of MCI progressing to AD, including: left hippocampus, left inferior lateral ventricle, left amygdala, right middle temporal gyrus, left fusiform gyrus, right amygdala, left cortical total volume, and brain parenchyma total volume. In the multivariate joint model, the atrophy of left hippocampus volume (α = -0.0009, P = 0.0010), the expansion of left lateral inferior ventricle volume (α = 0.0003, P = 0.0238), the atrophy of right middle temporal gyrus volume (α = -0.0002, P = 0.0036), and the accelerated atrophy of brain parenchyma total volume (α = 0.000005, P = 0.0008) were all significantly associated with the risk of disease transformation. Additionally, the covariate APOE ε4 allele remained a significant independent risk factor (γ = 0.6930, P < 0.0001).
conclusionLeft hippocampal atrophy, left inferior lateral ventricular enlargement, right middle temporal gyrus atrophy, and brain parenchyma total volume atrophy were independently associated with the risk of progression from MCI to AD, alongside the established genetic risk factor APOE ε4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.